Skip to main content
Caplight Logo









Mynvax

Mynvax

Private
Bangalore Urban, KarnatakaHealthcare & Life Scienceswww.mynvax.com

Last Round

Series A

Extension

May 24, 2024

Est. Valuation

$31M

Total Funding Raised

$6.8M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Mynvax is a biotechnology company that develops innovative drugs intended for use in influenza vaccines, focusing on treatments for flu and infectious diseases to support healthcare professionals in enhancing patient recovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2G

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

thermotolerant vaccineswarm vaccinescold-chain independentrecombinant protein vaccinesclinical-stage biotechprotein stabilizationrespiratory vaccinesvaccine development platforminfluenza vaccineCOVID-19 vaccinesubunit vaccinesbroadly protective vaccinesuniversal vaccineprotein engineeringvaccine licensingglobal health vaccines

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mynvax Comparables

Compare Mynvax with similar companies based on industry and business-model similarity.

Mynvax comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Imophoron
78%
Osivax
74%
HelixNano
74%

Mynvax Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMay 24, 2024
Series AJul 19, 2021
GrantAug 1, 2020
AngelOct 18, 2018

Mynvax Investors

Notable investors and investment history

Mynvax investors
InvestorRounds
Inviga Healthcare FundSeries A Extension
Kotak Mahindra TrusteeSeries A
Kotak Investment AdvisorsSeries A
1CrowdSeries A
AccelSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 214% MoM, reaching 1.3K.

  • Jul 28, 2026

    Monthly visitors increased 142% MoM, reaching 417.

Mynvax Filings

Explore SEC and related filing metadata, where available.

Mynvax filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Mynvax's valuation, stock price, and market status.

Is Mynvax a public or private company?

Mynvax is a private company.

What is the current stock price of Mynvax?

Mynvax is a private company with no public stock price. No recent secondary market data is available.

How much is Mynvax worth (valuation)?

Mynvax's valuation is estimated at $31.0M based on funding round data.

Can I buy Mynvax stock?

Mynvax shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Mynvax's last funding round?

Mynvax's most recent funding round was Series A Extension on May 24, 2024.

Who are the main investors in Mynvax?

Key investors in Mynvax include Inviga Healthcare Fund, Accel.

Will Mynvax IPO soon?

No public IPO plans have been announced for Mynvax.

How can I track Mynvax secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Mynvax's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBangalore Urban, Karnataka
Employee Range29
Year Founded2017
Last FundingMay 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?